Development of Neurochemical Normalization ("Agonist Substitution") Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909

Thomas Prisinzano, Kenner C. Rice, Michael H. Baumann, Richard B. Rothman

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

At the present time, there are no drugs are approved in the U.S. for the treatment of stimulant abuse. Based on a diverse body of preclinical data, sometimes termed the "dopamine hypothesis" of drug addiction, one approach to the treatment and prevention of stimulant abuse is the development of high affinity inhibitors of the dopamine transporter. This approach awaits clinical validation. As part of our program on the development of novel probes to study the structure and function of central nervous system, we have focused on the high affinity dopamine transport inhibitor GBR12909 (1-{2-[bis-(4-fluorophenyl) methoxy]ethyl}-4-(3-phenylpropyl)piperazine) as a tool to test the dopamine hypothesis in humans. Various analogues of GBR12909 have been evaluated both in vitro and in vivo. In particular, behavioral studies have shown that GBR12909 and several of its analogues decrease cocaine-maintained responding without affecting food-maintained responding and also appear to have reduced abuse liability as compared to cocaine in the monkey. Initial clinical studies in humans demonstrated that orally administered GBR12909 is safe, well-tolerated and achieves moderate occupancy of the dopamine transporter. This article will review the structure-activity relationships of GBR-type agents at the biogenic amine transporters, their biological activity and their potential as tools to test the dopamine hypothesis of cocaine addiction in humans.

Original languageEnglish
Pages (from-to)47-59
Number of pages13
JournalCurrent Medicinal Chemistry - Central Nervous System Agents
Volume4
Issue number1
DOIs
StatePublished - 2004

Keywords

  • Addiction
  • Cocaine
  • Dopamine
  • Dopamine transporter
  • GBR12909

ASJC Scopus subject areas

  • General Neuroscience
  • Neuropsychology and Physiological Psychology
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Development of Neurochemical Normalization ("Agonist Substitution") Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909'. Together they form a unique fingerprint.

Cite this